412 related articles for article (PubMed ID: 31879171)
1. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.
Jang HJ; Lee HS; Ramos D; Park IK; Kang CH; Burt BM; Kim YT
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1598-1610.e3. PubMed ID: 31879171
[TBL] [Abstract][Full Text] [Related]
2. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
4. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
[TBL] [Abstract][Full Text] [Related]
5. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D; Warren S; Arrondeau J; Boudou-Rouquette P; Mansuet-Lupo A; Biton J; Ouakrim H; Alifano M; Gervais C; Bellesoeur A; Kramkimel N; Tlemsani C; Burroni B; Duche A; Letourneur F; Si H; Halpin R; Creasy T; Herbst R; Ren X; Morel P; Cesano A; Goldwasser F; Leroy K
J Transl Med; 2019 Nov; 17(1):357. PubMed ID: 31684954
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
7. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
8. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
9. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
[TBL] [Abstract][Full Text] [Related]
10. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
12. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
13. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor.
Seo JS; Kim A; Shin JY; Kim YT
Sci Rep; 2018 Oct; 8(1):14576. PubMed ID: 30275546
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
16. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L
Front Immunol; 2021; 12():693314. PubMed ID: 34177954
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
Lou Y; Diao L; Cuentas ER; Denning WL; Chen L; Fan YH; Byers LA; Wang J; Papadimitrakopoulou VA; Behrens C; Rodriguez JC; Hwu P; Wistuba II; Heymach JV; Gibbons DL
Clin Cancer Res; 2016 Jul; 22(14):3630-42. PubMed ID: 26851185
[TBL] [Abstract][Full Text] [Related]
18. Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer.
Judd J; Borghaei H
Thorac Surg Clin; 2020 May; 30(2):199-206. PubMed ID: 32327178
[TBL] [Abstract][Full Text] [Related]
19. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
